Edwards Lifesciences, TAVR
In the latest quarter, 11 analysts provided ratings for Edwards Lifesciences EW, showcasing a mix of bullish and bearish ...
Shares of Edwards Lifesciences Corp. advanced 4.86% to $72.56 Tuesday, on what proved to be an all-around great trading ...
Stifel analyst Rick Wise upgraded Edwards Lifesciences (EW) to Buy from Hold with a price target of $90, up from $75. The firm said that TAVR, ...
Edwards Lifesciences Corp (EW) stock saw a decline, ending the day at $71.13 which represents a decrease of $-1.43 or -1.97% from the prior close of $72.56. The stock opened at $72.5 and touched a low ...
Edwards Lifesciences Veteran Katie Szyman Named Next Masimo CEO. The Irvine-based medical device maker last week announced ...
Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart ...
Wolfe Research has recently reduced Edwards Lifesciences Corp (EW) stock to Underperform rating, as announced on January 16, 2025, according to Finviz. Earlier, on December 16, 2024, BofA Securities ...
Edwards Lifesciences (EW) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known consensus ...
Geneos Wealth Management Inc. decreased its stake in shares of Edwards Lifesciences Co. (NYSE:EW – Free Report) by 2.3% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback